Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, has announced a collaboration with Galectin Therapeutics to use the BreathID® test to monitor patients in a Phase II study evaluating an investigational treatment for patients with cirrhosis associated with nonalcoholic steatohepatitis (NASH Cirrhosis).
Exalenz Bioscience develops and markets diagnostic and monitoring systems that use the exhaled breath to diagnose and help manage GI and liver conditions.
The company recently received approval from the U.S. Food and Drug Administration (FDA) of an investigational device exemption (IDE) for the study, which will include 156 patients in a multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate the safety and efficacy of Galectin Therapeutics’ GR-MD-O2 for the treatment of liver fibrosis and portal hypertension in patients with NASH Cirrhosis. As part of the study, Exalenz will investigate the clinical utility of its BreathID® to follow up the effect of treatment on patients with NASH Cirrhosis, compared to standard medical tests including hepatic venous pressure gradient (HVPG), liver biopsy results, and liver stiffness testing.
Enrolled participants will receive three breath-based tests: the first will be given during the screening stage, the second will be given at week 25 of treatment and the third will be given after the final dose of GR-MD-02. The results of this study will be used to further evaluate the efficacy of BreathID® and to optimize the company’s proprietary algorithm for monitoring the progression of NASH Cirrhosis to determine the clinical effectiveness of Galectin Therapeutics’ GR-MD-02 treatment among enrolled patients. Exalenz Bioscience expects that the optimized algorithm will continue to be applied to data collected in its other ongoing studies.
“It has been reported that NASH affects up to 10 percent of the U.S. population and represents a significant unmet medical need with no currently approved pharmacological treatment. Currently the only valid measures for diagnosis and follow up are invasive liver biopsy and HVPG,” said Raffi Werner, chief executive officer of Exalenz Bioscience. “We are excited to collaborate with Galectin Therapeutics in this clinical study and believe that our non-invasive, operator-independent, breath-based test has the potential to assist clinicians in determining patient suitability for treatment and to conveniently and cost-effectively monitor the effect of therapy at the point of care.”
“Early clinical data evaluating GR-MD-02 have been encouraging, demonstrating that our potential treatment for NASH Cirrhosis is safe, well-tolerated and achieved the targeted therapeutic dose,” said Peter G. Traber, M.D., Galectin’s chief executive officer, president and chief medical officer. “We are excited to be initiating a larger study in a broader patient population, and proud to be partnering with Exalenz Bioscience to further validate how their novel, non-invasive, breath-based technology can be used to select patients with NASH Cirrhosis who are candidates for therapy and to follow up the effect of our drug. The data from the BreathID® will provide valuable information for clinical stage pharmaceutical companies actively working on bringing new therapeutic options to patients.”
Source: PR Newswire